AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3802724 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mumol of lithium carbonate given orally in continuous doses
Number of subjects: 5
Study 3802724 — intervention group
Group type: COMPARATOR
Intervention: 100 mmol of oral NaCl added to the diet of volunteers receiving lithium
Number of subjects: 5
Study 30311061 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytotherapeutic drug (baicalin 190 mg; bromelain 50 mg; escin 30 mg)
Number of subjects: 82
Study 30311061 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 82
Study 30311061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 28668226 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal supplemental oxygen administration
Number of subjects: 48
Study 28668226 — intervention group
Group type: COMPARATOR
Intervention: No maternal supplemental oxygen administration
Number of subjects: 48
Study 26231742 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartilage palisades myringoplasty
Number of subjects: 55
Study 26231742 — intervention group
Group type: COMPARATOR
Intervention: Temporalis fascia myringoplasty
Number of subjects: 55
Study 23352193 — intervention group
Group type: EXPERIMENTAL
Intervention: SD-OCT imaging at 1-year and 2-year visits
Number of subjects: 299
Study 23352193 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hyperreflective foci (HF) presence
Number of subjects: 299
Study 23352193 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater number of baseline hyperreflective foci (HF)
Number of subjects: 299
Study 23352193 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater baseline AxD
Number of subjects: 299
Study 21234920 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy followed by standard PCI with stent implantation
Number of subjects: 137
Study 21234920 — intervention group
Group type: COMPARATOR
Intervention: Standard primary PCI
Number of subjects: 137
Study 21234920 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy
Number of subjects: 137
Study 19713429 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID infusion (administered via microdialysis catheter into the vastus lateralis muscle before, during, and for 4.5 h after exercise)
Number of subjects: 8
Study 19713429 — intervention group
Group type: COMPARATOR
Intervention: Control (unblocked leg)
Number of subjects: 8
Study 19713429 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID infusion
Number of subjects: 8
Study 17430734 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement containing soy isoflavones and Actaea racemosa L. (n = 60)
Number of subjects: 124
Study 17430734 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 64)
Number of subjects: 124
Study 14765851 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 200
Study 14765851 — intervention group
Group type: COMPARATOR
Intervention: Calcium-based phosphorus binders
Number of subjects: 200
Study 11580778 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (50 mg kg(‐1) body weight)
Number of subjects: 50
Study 11580778 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal volume of NaCl)
Number of subjects: 50
Study 9539618 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with fentanyl
Number of subjects: 0
Study 9539618 — intervention group
Group type: COMPARATOR
Intervention: Fiberscope
Number of subjects: 0
Study 9539618 — intervention group
Group type: COMPARATOR
Intervention: Laryngoscope
Number of subjects: 0
Study 8083910 — intervention group
Group type: COMPARATOR
Intervention: Early parenteral nutrition (TPN)
Number of subjects: 48
Study 8083910 — intervention group
Group type: COMPARATOR
Intervention: Jejunal feeding (ENT)
Number of subjects: 48
Study 2691130 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (per)
Number of subjects: 103
Study 2691130 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pla)
Number of subjects: 103
Study 4533701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic administration of PGF2alpha
Number of subjects: 1500
Study 4533701 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-methyl-PGF2alpha (2.5 mg intra-amniotic injection)
Number of subjects: 1500
Study 4533701 — intervention group
Group type: EXPERIMENTAL
Intervention: 16,16-dimethyl-PGE2 (repeated oral administration)
Number of subjects: 1500
Study 4533701 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline
Number of subjects: 1500
Study 42628 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide lactam (5 mg)
Number of subjects: 40
Study 42628 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordiazepam (10 mg)
Number of subjects: 40
Study 42628 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (15 mg)
Number of subjects: 40
Study 30829100 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-attenuated tetravalent dengue virus (TDEN) vaccine
Number of subjects: 244
Study 30829100 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or the precursor live-attenuated TDEN vaccine)
Number of subjects: 244
Study 29072415 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management group therapy for 18 hours
Number of subjects: 104
Study 29072415 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 104
Study 25789456 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat health warning (HHW) and water delivery (HHW+W)
Number of subjects: 1072
Study 25789456 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat health warning (HHW)
Number of subjects: 1072
Study 25789456 — intervention group
Group type: EXPERIMENTAL
Intervention: Household water delivery (part of HHW+W)
Number of subjects: 1072
Study 25789456 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1072
Study 23921361 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with intrauterine insemination (IUI)
Number of subjects: 99
Study 23921361 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 99
Study 21161715 — intervention group
Group type: EXPERIMENTAL
Intervention: BOTOX®
Number of subjects: 65
Study 21161715 — intervention group
Group type: COMPARATOR
Intervention: Xeomin®
Number of subjects: 65
Study 21161715 — intervention group
Group type: EXPERIMENTAL
Intervention: BOTOX® and Xeomin®
Number of subjects: 65
Study 19213976 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine controlled-release (12.5 mg-50 mg/day)
Number of subjects: 72
Study 19213976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 17694662 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining normal body temperature with water market and forced air heater
Number of subjects: 50
Study 17694662 — intervention group
Group type: COMPARATOR
Intervention: Monitoring body temperature without treatment
Number of subjects: 50
Study 15238968 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach clinic consultations
Number of subjects: 0
Study 15238968 — intervention group
Group type: COMPARATOR
Intervention: Main base clinic consultations
Number of subjects: 0
Study 12478881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (up to 800 mg/day)
Number of subjects: 15
Study 12478881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9809930 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonist-based strategy (verapamil)
Number of subjects: 27000
Study 9809930 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker/diuretic-based strategy (atenolol/hydrochlorothiazide)
Number of subjects: 27000
Study 7659626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed health education booklet
Number of subjects: 3913
Study 7659626 — intervention group
Group type: COMPARATOR
Intervention: Control group (no booklet)
Number of subjects: 3913
Study 2576365 — intervention group
Group type: EXPERIMENTAL
Intervention: picumast dihydrochloride 1 mg twice daily for 6 weeks
Number of subjects: 107
Study 2576365 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 107
Study 2576365 — intervention group
Group type: EXPERIMENTAL
Intervention: picumast dihydrochloride
Number of subjects: 107
Study 8748 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic propranolol
Number of subjects: 54
Study 8748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 54
Study 8748 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 54
Study 8748 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 54
Study 8748 — intervention group
Group type: EXPERIMENTAL
Intervention: D-propranolol
Number of subjects: 54
Study 30523908 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-lactate-containing mouthwash (10 ml/30 s)
Number of subjects: 16
Study 30523908 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-lactate-containing mouthwash (15 ml/60 s)
Number of subjects: 16
Study 30523908 — intervention group
Group type: COMPARATOR
Intervention: Rinse without zinc-lactate (3 droplets/10 ml tap water/30 s)
Number of subjects: 16
Study 30523908 — intervention group
Group type: COMPARATOR
Intervention: Tap water (10 ml/30 s)
Number of subjects: 16
Study 29176548 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic staff determining replenishment needs
Number of subjects: 0
Study 29176548 — intervention group
Group type: COMPARATOR
Intervention: Nursing staff determining replenishment needs
Number of subjects: 0
Study 29176548 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic staff
Number of subjects: 0
Study 29176548 — intervention group
Group type: COMPARATOR
Intervention: Nursing staff
Number of subjects: 0
Study 29176548 — intervention group
Group type: COMPARATOR
Intervention: Comparison of outstanding orders between groups
Number of subjects: 0
Study 29176548 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative risk of outstanding orders
Number of subjects: 0
Study 29176548 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of cases required for an outstanding order
Number of subjects: 0
Study 25351498 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (60 mg daily in tapering doses)
Number of subjects: 192
Study 25351498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 25351498 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 192
Study 23804278 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clopidogrel (CLO) 75 mg
Number of subjects: 9
Study 23804278 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin (ASA) 81 mg
Number of subjects: 9
Study 23804278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 23804278 — intervention group
Group type: COMPARATOR
Intervention: Control site for NO-dependent vasodilation
Number of subjects: 9
Study 20938374 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 45
Study 20938374 — intervention group
Group type: COMPARATOR
Intervention: Podophyllotoxin 0.5% solution
Number of subjects: 45
Study 19910376 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for breast cancer prevention
Number of subjects: 815
Study 16802350 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 315
Study 16802350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 12723101 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Motion Toothbrush
Number of subjects: 126
Study 12723101 — intervention group
Group type: COMPARATOR
Intervention: Oral-B CrossAction Toothbrush
Number of subjects: 126
Study 11137927 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 158
Study 11137927 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulants (OAs)
Number of subjects: 158
Study 9869369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine (P) administered by the ocular route
Number of subjects: 0
Study 9869369 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 8018980 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine
Number of subjects: 241
Study 8018980 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 241
Study 2589233 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) 24 mg in 5 doses
Number of subjects: 25
Study 2589233 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (MCP) 1 mg/kg as a single dose
Number of subjects: 25
Study 782470 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramiverine
Number of subjects: 51
Study 782470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 31062692 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb
Number of subjects: 1845
Study 31062692 — intervention group
Group type: COMPARATOR
Intervention: XIENCE
Number of subjects: 1845
Study 30573277 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaratumab + mitoxantrone/prednisone
Number of subjects: 123
Study 30573277 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone/prednisone
Number of subjects: 123
Study 29944516 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intravenous methylprednisolone 125 mg (group MP)
Number of subjects: 134
Study 29944516 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline intravenous (group C)
Number of subjects: 134
Study 27522037 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter tastant mixture (0.88 mg SOA, 0.088 mg QE, 0.22 mg RF)
Number of subjects: 60
Study 27522037 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-bitter)
Number of subjects: 60
Study 25175079 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraomohyoid neck dissection (SOND)
Number of subjects: 322
Study 25175079 — intervention group
Group type: COMPARATOR
Intervention: Modified radical neck dissection (MRND)
Number of subjects: 322
Study 22820896 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 60 mg
Number of subjects: 24
Study 22820896 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg
Number of subjects: 24
Study 22820896 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 20 mg
Number of subjects: 24
Study 22820896 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 40 mg
Number of subjects: 24
Study 22820896 — intervention group
Group type: COMPARATOR
Intervention: Dalcetrapib alone
Number of subjects: 24
Study 22820896 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (various doses)
Number of subjects: 24
Study 21070458 — intervention group
Group type: EXPERIMENTAL
Intervention: LED photomodulation
Number of subjects: 33
Study 21070458 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control)
Number of subjects: 33
Study 17692727 — intervention group
Group type: EXPERIMENTAL
Intervention: RNF (Rebif® New Formulation, 44 μg/0.5 mL SC tiw)
Number of subjects: 260
Study 17692727 — intervention group
Group type: COMPARATOR
Intervention: EVIDENCE study (approved formulation of IFN‐β1a, identical regimen)
Number of subjects: 260
Study 16332661 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (12 mg Fe/d for 6 d/wk for 35 wk)
Number of subjects: 330
Study 16332661 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolytic iron (12 mg Fe/d for 6 d/wk for 35 wk)
Number of subjects: 330
Study 16332661 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-reduced iron (12 mg Fe/d for 6 d/wk for 35 wk)
Number of subjects: 330
Study 16332661 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fortification)
Number of subjects: 330
Study 11824947 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 6
Study 11824947 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg
Number of subjects: 6
Study 11824947 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (both dosages)
Number of subjects: 6
Study 9915379 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoprene lumbar brace
Number of subjects: 40
Study 7770734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Psychiatric Community Care (IPCC)
Number of subjects: 873
Study 7770734 — intervention group
Group type: COMPARATOR
Intervention: Standard VA care
Number of subjects: 873
Study 2279212 — intervention group
Group type: EXPERIMENTAL
Intervention: methohexitone
Number of subjects: 18
Study 2279212 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 383171 — intervention group
Group type: EXPERIMENTAL
Intervention: radio-chemotherapy combined with the methanol extraction residue of BCG (MER)
Number of subjects: 53
Study 383171 — intervention group
Group type: COMPARATOR
Intervention: radio-chemotherapy
Number of subjects: 53
Study 31698920 — intervention group
Group type: EXPERIMENTAL
Intervention: Button-activated ENDS
Number of subjects: 17
Study 31698920 — intervention group
Group type: COMPARATOR
Intervention: Other ENDS device
Number of subjects: 17
Study 31698920 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ENDS devices
Number of subjects: 17
Study 31136817 — intervention group
Group type: EXPERIMENTAL
Intervention: Embrace™ WetBond™ (moisture tolerant resin sealant)
Number of subjects: 40
Study 31136817 — intervention group
Group type: COMPARATOR
Intervention: Fuji TRIAGE® (glass ionomer sealant)
Number of subjects: 40
Study 31136817 — intervention group
Group type: EXPERIMENTAL
Intervention: DIAGNOdent readings
Number of subjects: 40
Study 27279368 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 25998755 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion (HSM)
Number of subjects: 432
Study 25998755 — intervention group
Group type: COMPARATOR
Intervention: Conventional moxibustion
Number of subjects: 432
Study 25998755 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection with sodium hyaluronate
Number of subjects: 432
Study 24414739 — intervention group
Group type: EXPERIMENTAL
Intervention: High FeNO group (≥80 ppb)
Number of subjects: 93
Study 24414739 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate FeNO group (40-79 ppb)
Number of subjects: 93
Study 24414739 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FeNO group (<40 ppb)
Number of subjects: 93
Study 24414739 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-to-low FeNO group (<40 ppb)
Number of subjects: 93
Study 22939848 — intervention group
Group type: EXPERIMENTAL
Intervention: Central Position (CE)
Number of subjects: 0
Study 22939848 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Visual Half-Field (RVF)
Number of subjects: 0
Study 22939848 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Visual Half-Field (LVF)
Number of subjects: 0
Study 22939848 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 0
Study 19542104 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 15 microg kg(‐1) 90 s before propofol injection
Number of subjects: 120
Study 19542104 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.1% premixed with propofol 3 mg kg(‐1) over 15 s
Number of subjects: 120
Study 19542104 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of alfentanil and lidocaine
Number of subjects: 120
Study 17043847 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 112
Study 17043847 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (Control)
Number of subjects: 112
Study 17043847 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (VDD)
Number of subjects: 112
Study 17043847 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypovitaminosis D
Number of subjects: 112
Study 17043847 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of vitamin D
Number of subjects: 112
Study 17043847 — intervention group
Group type: EXPERIMENTAL
Intervention: I-PTH and ALP levels
Number of subjects: 112
Study 15241912 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Sensitive Maximum Strength dentifrice containing 5% potassium nitrate
Number of subjects: 0
Study 15241912 — intervention group
Group type: COMPARATOR
Intervention: Market leader dentifrice containing 5% potassium nitrate
Number of subjects: 0
Study 12114412 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryostatin 1 (50 microg/m(2)) administered as a 24‐h continuous infusion on days 1 and 11 before and after high-dose 1-beta-D-arabinofuranosylcytosine (HiDAC; 1.5 g/m(2) every 12 h x 4 on days 2 and 3, and 9 and 10)
Number of subjects: 23
Study 12114412 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryostatin 1 (50 microg/m(2)) with HiDAC
Number of subjects: 23
Study 12114412 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryostatin 1 (50 microg/m(2))
Number of subjects: 23
Study 9690979 — intervention group
Group type: EXPERIMENTAL
Intervention: milnacipran 100 mg/day
Number of subjects: 289
Study 9690979 — intervention group
Group type: EXPERIMENTAL
Intervention: milnacipran 200 mg/day
Number of subjects: 289
Study 9690979 — intervention group
Group type: COMPARATOR
Intervention: fluoxetine 20 mg/day
Number of subjects: 289
Study 10354909 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized Peak Pressure (NPP)
Number of subjects: 0
Study 10354909 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Contact Ratio (PCR)
Number of subjects: 0
Study 2031969 — intervention group
Group type: COMPARATOR
Intervention: Intensive consolidation chemotherapy (SIC)
Number of subjects: 106
Study 2031969 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplant (auto-BMT)
Number of subjects: 106
Study 2031969 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplant (allo-BMT)
Number of subjects: 106
Study 6663042 — intervention group
Group type: EXPERIMENTAL
Intervention: Proficient esophageal speakers
Number of subjects: 24
Study 6663042 — intervention group
Group type: COMPARATOR
Intervention: Nonproficient esophageal speakers
Number of subjects: 24
Study 30171041 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise 1×/week for 6 weeks during active treatment
Number of subjects: 25
Study 30171041 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise 1×/week for 6 weeks
Number of subjects: 25
Study 31597550 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted 1-SD log-transformed increase in Lp(a) concentrations
Number of subjects: 446696